This will mainly be because of the growth in dr-ug development, increase in the demand for analysis in clinical diagnostics, and the usage of flow cytometry for research purposes. For instance, this technology is widely used in in-vitro molecular studies and cancer research.

Healthcare centers accomplish immunophenotyping for the analysis of primary immunodeficiency ailments, lymphoma and leukemia, and paroxysmal nocturnal hemoglobinuria (PNH), and reporting of immunity status in patients with HIV contagions and other malignant diseases. For example, globally, about 20 million new cancer cases were reported in 2020, and this number will likely reach around 30 million by 2040.